Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas
Version 2 2024-06-13, 16:16Version 2 2024-06-13, 16:16
Version 1 2015-03-17, 11:51Version 1 2015-03-17, 11:51
journal contribution
posted on 2024-06-13, 16:16authored byGB McCowage, HS Friedman, A Moghrabi, T Kerby, L Ferrell, E Stewart, M Duncan-Brown, HE Fuchs, R Tien, RE McLendon, L Meier, J Kurtzberg, D Ashley, OM Colvin, DC Longee
Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophosphamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma.